View
0
Download
0
Category
Preview:
Citation preview
This is one of five questionnaires that Member States are invited to complete ahead of the 40thWHO Expert Committee on Drug Dependence. This questionnaire will ask you about extracts andtinctures containing cannabidiol (CBD).
--------------------------------------------------------------------------------------------------
The questionnaire will take about 15-25 minutes to complete. You may return to the questionnaireto amend your responses at any time until the closure of the questionnaire.
To commence the questionnaire, you will first be asked to indicate that you agree to WHO datasharing policy. The responses of this questionnaire will be compiled into a report that will bepublicly available on the WHO ECDD website. The name of your country may be presentedalongside questionnaire data unless you indicate that you wish for your country name to beanonymised in the final report.
If you wish to submit any information to the attention of the ECDD Secretariat, you will be invited toupload documents at the end of the questionnaire.
We thank you in advance for taking the time to complete this questionnaire.
Introduction
WHO ECDD Questionnaire: Cannabidiol (CBD)
General Information
WHO ECDD Questionnaire: Cannabidiol (CBD)
Name
1. Focal point contact details*
2. Please indicate your country*
Statement of policy on data sharing Data are the basis for all sound public health actions and the benefits of data sharing are widelyrecognized, including scientific and public health benefits. Whenever possible, WHO wishes topromote the sharing of health data, including but not restricted to surveillance and epidemiologicaldata.
In this connection, and without prejudice to information sharing and publication pursuant to legallybinding instruments, by providing data to WHO, the [Ministry of Health][other responsiblegovernmental entity] of [Country]:
Confirms that all data to be supplied to WHO (including but not limited to the types listed in Annex3) hereunder have been collected in accordance with applicable national laws, including dataprotection laws aimed at protecting the confidentiality of identifiable persons;
Agrees that WHO shall be entitled, subject always to measures to ensure the ethical and secure useof the data, and subject always to an appropriate acknowledgement of [Country]:
- to publish the data, stripped of any personal identifiers (such data without personal identifiersbeing hereinafter referred to as “the Data”) and make the Data available to any interested party onrequest (to the extent they have not, or not yet, been published by WHO) on terms that allow non-commercial, not-for-profit use of the Data for public health purposes (provided always thatpublication of the Data shall remain under the control of WHO);
- to use, compile, aggregate, evaluate and analyse the Data and publish and disseminate the resultsthereof in conjunction with WHO’s work and in accordance with the Organization’s policies andpractices.
Except where data sharing and publication is required under legally binding instruments (IHR, WHONomenclature Regulations 1967, etc.), the [Ministry of Health][other responsible governmentalentity] of [Country] may in respect of certain data opt out of (any part of) the above, by notifyingWHO thereof in writing at the following address, provided that any such notification shall clearlyidentify the data in question and clearly indicate the scope of the opt-out (in reference to the above), and provided that specific reasons shall be given for the opt out.
ecddsecretariat@who.int
WHO Data Sharing Policy
WHO ECDD Questionnaire: Cannabidiol (CBD)
3. Please confirm that you agree*
I agree for the information provided in this questionnaire to be published in a report
General cannabis information
WHO ECDD Questionnaire: Cannabidiol (CBD)
4. Do you have any information about the use of CBD for any purpose (including medical or non-medicaluse) in your country?
*
Yes
No - you will be directed to the end of the questionnaire
This page will ask you about approved medical use of CBD.
Medical use
WHO ECDD Questionnaire: Cannabidiol (CBD)
5. At national level, is CBD legally approved for medical use in your country?*
Yes
No
Other (please specify)
Medical use: Therapeutic indications
WHO ECDD Questionnaire: Cannabidiol (CBD)
6. Please indicate any approved therapeutic indications for the use of CBD in your country
Epilepsy
Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury
Arthritis
Dystonia
Huntington’s disease
Parkinson’s disease
Tourette’s syndrome
Glaucoma
Anxiety
Depression
PTSD
Schizophrenia /psychosis
Alzheimer’s disease/ dementia
Skin disease
Irritable bowel syndrome
Inflammatory bowel disease
Liver disease
Obesity/ diabetes
Cancer
HIV/AIDS
Chronic pain
Crohn's disease
Attention Deficit Disorder (ADD)
None specified
Other (please specify)
7. Please indicate any symptoms that CBD is approved to treat
Acute pain
Chronic non-cancer pain
Cancer pain
Nausea/ vomiting
Appetite stimulant
Headaches/ migraines
Muscle spasms
Seizures
Sleep problems
Alcohol withdrawal symptoms
Opioid withdrawal symptoms
Palliative care
Other (please specify)
Name of marketed product& CBD /THC content (ifknown):
Name of marketed product& CBD /THC content (ifknown):
Name of marketed product& CBD /THC content (ifknown):
Name of marketed product& CBD /THC content (ifknown):
Name of marketed product& CBD /THC content (ifknown):
8. Please indicate whether there are any permitted marketed products of CBD.
9. Are there any ongoing approved clinical trials in your country that are developing CBD for medicaluse?
Yes
No
Other (please specify)
Product name
Product name
Product name
Product name
Product name
Product name
10. Please indicate product name/ trial number/ study phase of any ongoing trials that are developingproducts of CBD for medical use
Medical use: Access
WHO ECDD Questionnaire: Cannabidiol (CBD)
11. Do individuals require a prescription to obtain medical CBD?
Yes
No
N/A
Other (please specify)
12. What types of professionals are allowed to prescribe CBD?
Medical doctor / psychiatrist
Osteopath
Nurse/nurse prescriber
Pharmacist
Psychologist
Physiotherapist
Healthcare worker
No prescription is required
Other (please specify)
13. What kinds of settings are approved to legally dispense CBD in your country?
At a doctor's office
Pharmacies
Online
Retail shops
Licensed/specialised cannabis dispensaries
Hospitals
Outpatient clinics
Palliative care facilities
Nursing homes
Other (please specify)
14. If patients use medical CBD on prescription or recommendation of a health professional, will they bereimbursed for the costs of their medication?
Yes, they will be reimbursed by National Health Services
Yes, each health insurance company in the country will reimburse the patients
Some health insurances do reimburse for the costs, others do not
Patients have to make extra health insurance arrangements to be reimbursed
No, patients cannot be reimbursed
Other (please specify)
15. Are any clinical guidelines used in your country for the prescribing of medical CBD?
No
N/A
Yes (please specify)
16. Is there a regulatory agency in your country that monitors CBD for medical use?
No
N/A
Yes (please specify)
The number hassubstantially
increased
The number hasslightly
increased
The number hasremained the
sameThe number hasslightly reduced
The number hassubstantially
reducedDon't know/
unsure
CBD
17. How would you describe the trend in the number of users of CBD for medical use over the last 3 years?
This section will ask about the general policies in your country towards cannabis-relatedsubstances for medical use
Medical use: National legislation
WHO ECDD Questionnaire: Cannabidiol (CBD)
Yes, my country has changed its legislation No, my country has not changed its legislation
CBD
Unknown/ Other (please specify)
18. In the past 3 years, has your country changed its national legislation around access to cannabis-related substances for medical use?
19. If yes, what types of legislative changes has your country made for medical use of CBD?
Change to the legal status of medical cannabis
Changes to the supply of medical cannabis (e.g. changes in licensing, import – or export of products)
Changes to access to medical cannabis (e.g. variety in products, therapeutic indications etc)
Other (please specify)
Yes, my country is preparing changes in its
legislationNo, my country is not preparing changes in its
legislation
CBD
Unknown/ Other (please specify)
20. Is your country currently considering changes to its national legislation around access to cannabis andcannabis-related substances for medical use?
There would be /hasbeen a
substantially negativeimpact on public
health
There wouldbe /has been a
slightlynegativeimpact on
public health
There wouldbe/ has beenno impact onpublic health
There wouldbe/ has been aslightly positive
impact onpublic health
There would be/ hasbeen a
substantially positiveimpact on public
healthDon't know/
unsure
Increased availabilityfor medical use
Decreased availabilityfor medical use
Please explain your response:
21. In your opinion, how do you feel the changed legislation around access to CBD for medical usewould impact / has impacted public health in your country?
The next section will ask you about non-medical use of CBD in your country. Non-medical useincludes both recreational use, and use for self-medication purposes.
Non-medical Use
WHO ECDD Questionnaire: Cannabidiol (CBD)
22. On a national level, is CBD legally available for non-medical use in your country?*
Yes
No
Other (please specify)
23. Is CBD used for cultural, ceremonial, or religious purposes in your country?
No
Unknown
Yes (please specify)
24. Does your country collect prevalence data around the use of CBD?
Yes
No
N/A
Unknown
Prevalence of non-medical cannabis use
WHO ECDD Questionnaire: Cannabidiol (CBD)
Number (or % ofpopulation) used in lifetime
Number (or % ofpopulation) used in the lastyear
Number (or % ofpopulation) used in thepast month
Year of survey data
Prevalence by age group(if known)
25. Prevalence of use of CBD amongst adults ( over 18 years of age)
Number (or % ofpopulation) used in lifetime
Number (or % ofpopulation) used in the lastyear
Number (or % ofpopulation) used in thepast month
Year of survey data
Prevalence data by agegroup (if available)
26. Prevalence of use of CBD for non-medical use amongst young people ( below 18 years of age)
There has been asignificant increase
in use
There has been aslight increase in
useThere has been no
change in use
There has been aslight decrease in
use
There has been asignificant decrease
in use
Non-medical use byadults
Non-medical use byyoung people (belowage 18)
Comments:
27. How would you describe the number of users CBD for non-medical use over the last 3 years in yourcountry?
Public health impact of use: Primary Care
WHO ECDD Questionnaire: Cannabidiol (CBD)
28. Does your country collect data about presentations to primary care settings due to the use of CBD?
Yes
No
Unsure
Primary Care II
WHO ECDD Questionnaire: Cannabidiol (CBD)
Number ofpresentations relating tosubstance alone
Number ofpresentations relating tosubstance in combinationwith other substances
Year of data collection
29. Number of primary care presentations relating to CBD
30. Does your country collect data about presentations to emergency care settings due to the use ofCBD?
Yes
No
Unsure
Public health: Emergency settings
WHO ECDD Questionnaire: Cannabidiol (CBD)
Relating to substancealone:
Relating to substance withother substances:
Year of data collection
31. Number of individuals in the past year presenting to emergency settings relating to the use of CBD
32. Please list the adverse effects presented for CBD at the emergency room/department
Injuries related to impaired driving
Injuries related to accidents/falls
Prenatal exposure
Cannabis use disorders / withdrawal
Psychiatric comorbidity
Respiratory problems
33. Does your country collect data about presentations to substance misuse treatment settings due tothe use of CBD?
Yes
No
Unsure
Public health: Substance misuse treatment
WHO ECDD Questionnaire: Cannabidiol (CBD)
Relating to substancealone
Relating to substance andother substances
Year of data collection
34. Number of individuals in the past year presenting to substance misuse treatment due to CBD
35. Does your country collect data about calls to poison centres due to the use of CBD?
Yes
No
Unsure
Public health impact: Poison control centres
WHO ECDD Questionnaire: Cannabidiol (CBD)
Relating to substancealone
Relating to substance andother substances:
Year of data collection
36. Number of calls to poison control centres due to the use of CBD
37. Does your country collect data about cases of impaired driving due to the use of CBD?
Yes
No
Unsure
Public health impact: Impaired driving
WHO ECDD Questionnaire: Cannabidiol (CBD)
Relating tosubstance alone
Relating to substance andother substances
38. Number of cases of impaired driving due to CBD
This section will ask you about your national policies on the non-medical use of cannabis
Non-Medical Use: National legislation
WHO ECDD Questionnaire: Cannabidiol (CBD)
Yes, my country has changed its legislation No, my country has not changed its legislation
CBD
Please explain your response:
39. In the past 3 years, has your country changed its national legislation around access to CBD fornon-medical use?
40. If yes, what types of legislative changes has your country made for non-medical use of CBD?
Yes, my country is preparing changes in its
legislationNo, my country is not preparing changes in its
legislation
Cannabis plant andcannabis resin
Please explain your response:
41. Is your country currently considering changes to its national legislation around access to CBD fornon-medical use?
There would be/has been asignificantly
negative impacton public health
There would be/has been a
slightly negativeimpact on public
health
There would be/has been no
impact on publichealth
There would be/has been a
slightly positiveimpact on public
health
There would be/has been asignificantly
positive impacton public health
Don't know/unsure
Increased availability fornon-medical use
Decreased availability fornon-medical use
Please explain your response:
42. In your opinion, how do you feel the changed legislation around access to CBD for non-medicaluse would impact / has already impacted public health in your country?
In this section, you may provide any additional information that you wish for the WHO ExpertCommittee to consider. You can provide comments on cannabis substances for medical non-medical and medical use. You may also wish to upload data or documents for the committee to consider. This may includeresults of national surveys. For the transmission of sensitive or highly confidential information,please submit these documents directly to the ECDD at ecddsecretariat@who.int
Additional comments / information
WHO ECDD Questionnaire: Cannabidiol (CBD)
43. Comments
No file chosen
44. File upload
Choose File
No file chosen
45. File upload
Choose File
No file chosen
46. File upload
Choose File
Recommended